Official AMFI data
Arthkar
ICICI Prudential

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund

Sectoral / ThematicEquity SEBI-regulated

NAV (Direct-Growth)

₹47.3100

As of 3 Jul 2026 · AMFI

AUM

₹6.5K Cr

Expense ratio

0.87%

1Y returns

+9.76%

cat 12.11%

3Y CAGR

+26.57%

cat 22.73%

5Y CAGR

+16.72%

cat 13.72%

Std deviation 3Y

+16.45%

cat 16.29%

In plain English

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is a Sectoral / Thematic scheme from ICICI Prudential. The portfolio is ~100% in equities. Long-run track record: about 16.7% CAGR over 5 years. Volatility is typical for equity — 20–30 % drawdowns happen during market stress. Worst historical drawdown: -21% in Mar 2020, recovered in 1 months. Wrong fit if you need this money in less than 7 years.

Auto-generated from holdings, returns and risk data. No paid placement, no copy-pasted boilerplate.

NAV history

Showing Direct · Growth · INF109KC1GH2

NAV (Direct-Growth)

₹47.3100

Last 1Y

+10.51%

Jul 25Min ₹39.41 · Max ₹47.31 · 244 ptsJul 26

Drawdown stories

The crashes you should know about — and how long the fund took to recover.

Mar 2020

-20.6%

Peak ₹11.42 on 14 Feb 2020 → trough ₹9.07 on 23 Mar 2020 (1 months down).

Recovered in 1 months· 8 Apr 2020

Jun 2022

-18.1%

Peak ₹22.55 on 15 Sept 2021 → trough ₹18.46 on 17 Jun 2022 (9 months down).

Recovered in 12 months· 26 Jun 2023

Feb 2025

-16.2%

Peak ₹43.32 on 2 Jan 2025 → trough ₹36.30 on 28 Feb 2025 (2 months down).

Recovered in 5 months· 15 Jul 2025

Oct 2019

-15.2%

Peak ₹11.02 on 7 Sept 2018 → trough ₹9.34 on 7 Oct 2019 (13 months down).

Recovered in 3 months· 17 Jan 2020

Computed from the full NAV history. We show drawdowns deeper than 10%, sorted by depth.

Honesty score

A 1–5 grade on the dimensions other sites won't surface — expense bloat, AUM bloat, concentration, mandate compliance.

4

Honesty score

4 / 5

Solid scheme on the dimensions we check. No red flags.

  • Expense ratio

    0.87% — typical for category.

  • AUM size

    ₹6.5K Cr.

  • Sector concentration

    Top 3 sectors = 99.8% — heavy concentration risk.

Computed from expense ratio, AUM, sector concentration and SEBI mandate compliance. No paid review.

Performance

Returns for various periods, with category average and peer rank.

PeriodReturnsCategory avgRank
1W+3.04%+0.29%4/ 18
1M+6.92%+3.93%2/ 18
3M+6.81%+5.61%13/ 18
6M+8.31%+12.10%17/ 18
YTD+8.71%+11.97%17/ 18
1Y+9.76%+12.11%13/ 17
2Y+14.61%+12.10%5/ 14
3Y+26.57%+22.73%2/ 10
5Y+16.72%+13.72%2/ 9
7Y+22.47%+19.14%2/ 8
10Y+13.62%

Portfolio composition

Asset allocation

  • Equity99.82%
  • Cash0.18%

By market cap

  • Large cap36.67%
  • Mid cap23.19%
  • Small cap31.98%
  • Others8.16%

Concentration

Holdings

40

Avg market cap

₹46.1K Cr

Top 10 stocks

60.73%

Top 5 stocks

40.33%

Top 3 sectors

99.82%

Top holdings

Top 15 positions by weight, latest disclosure.

#InstrumentSectorWeight
  • 1

    Sun Pharmaceuticals Industries Ltd

    12.11%
  • 1

    Sun Pharmaceuticals Industries Ltd

    12.09%
  • 2

    Cipla Ltd

    9.23%
  • 2

    Dr Reddy's Laboratories Ltd

    7.70%
  • 3

    Cipla Ltd

    7.45%
  • 4

    Mankind Pharma Ltd

    7.03%
  • 3

    Mankind Pharma Ltd

    7.01%
  • 4

    Biocon Ltd

    6.08%
  • 5

    Divi's Laboratories Ltd

    6.06%
  • 5

    Dr Reddy's Laboratories Ltd

    5.97%
  • 6

    Divi's Laboratories Ltd

    5.91%
  • 6

    Treps

    5.18%
  • 7

    Net Current Assets

    5.00%
  • 8

    Biocon Ltd

    4.71%
  • 9

    Cohance Lifesciences Ltd

    4.37%

Fundamentals (vs category)

Portfolio-weighted ratios, compared with the category average.

MetricFundCategory avgDiff
  • P/E ratio36.3041.09-4.79
  • P/B ratio4.185.83-1.65
  • Price / Sales3.965.71-1.75
  • Price / Cash Flow24.6430.54-5.90
  • Dividend yield0.67%0.63%+0.04
  • Return on equity (ROE)13.60%16.57%-2.97

Risk metrics

Standard deviation, Sharpe, Sortino, Beta — all vs category average.

Metric1Y3Y5YCat 1YCat 3YCat 5Y
  • Standard deviation

    Volatility — lower means steadier returns.

    17.2816.4515.4014.9216.2915.44
  • Sharpe ratio

    Risk-adjusted return — higher is better.

    0.341.140.740.480.980.58
  • Sortino ratio

    Like Sharpe but only counts downside volatility.

    0.562.001.230.831.710.94
  • Beta

    1 = moves with the market. <1 = less volatile.

    0.940.960.930.940.950.94

Peers in Sectoral / Thematic

Other schemes in the same SEBI category, ranked by AUM.

Available plans & options

PlanOptionFull nameISIN

Click a plan to see its NAV and chart above. Direct plans have lower expense ratios than Regular — same portfolio, more of the return stays with you.